J.P. Morgan Notebook Day 3: Regeneron, AstraZeneca CRISPR And Juno
This article was originally published in Scrip
You may also be interested in...
Three CRISPR/Cas9 patent owners and four companies that license the intellectual property – CRISPR, Intellia, Caribou and ERS – signed a formal agreement to protect their patent rights and cross-license necessary IP while a patent interference proceeding is ongoing.
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.